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Interaction of hypertension and diabetes on renal function in black
NIDDM subjects. We studied renal function of 194 black subjects with
duration of diagnosed NIDDM from 1 month to 36 years to determine the
interaction of hypertension and diabetes on nephropathy. Renal function
was assessed by isotopic GFR and RPF studies, and serum creatinine. One
hundred seventeen of the 194 subjects had 24-hour urinaly albumin
excretion (AER). AER > 300 mg/24 h correlated with longer duration of
NIDDM, decrease in GFR and RPF, and rise in serum Cr, and all subjects
were hypertensive. AER 30 to 300 mg/24 h also correlated with a longer
duration of NIDDM and 80% had hypertension. When 194 subjects were
grouped according to duration of NIDDM and the presence or absence of
hypertension, subjects who remained normotensive had normal renal
function. In hypertensive subjects a decrease in GFR occurred with
duration of NIDDM > 1 year and decrease in RPF with duration of
NIDDM > 5 years. In hypertensive subjects with NIDDM > 10 years,
36% had impaired renal function (GFR < 80 ml/min/1.73 m2 or serum
creatinine > 1.4 mg/dl) and 75% had microalbuminuria or clinical
proteinuria. Within this group, those subjects who developed hypertension
after their diagnosis of diabetes were likely to have evidence of nephrop-
athy as compared to those subjects whose hypertension was diagnosed
prior to or simultaneous with their diabetes: 17 of 20 (85%) versus 7 of 13
(54%), respectively (P = 0.05). These data provide insight into the
relationship between hypertension and diabetes in the development of
nephropathy in black NIDDM individuals.
The prevalence of end-stage renal disease (ESRD) in non-
insulin-dependent diabetes mellitus (NIDDM) populations varies
considerably (3 to 40%) depending on race [1—5]. In black subjects
with NIDDM in the USA, ESRD occurs in 15 to 20%; this is
4.3-fold higher than the number of white NIDDM subjects [1—3].
While there is some controversy, a recent population based study
has suggested that blacks with diabetes have a higher rate of
ESRD independent of their increased prevalence of hypertension
[6]. Mexican Americans with NIDDM have a four- to six-fold
increase in ESRD as compared to non-Hispanic white subjects
with NIDDM despite the lower prevalence of essential hyperten-
sion [4]. In the Pima Indians, the rate of diabetic nephropathy is
equal to or greater than that of white insulin-dependent diabetes
mellitus (IDDM) subjects, and proteinuria is predictive of dia-
betic nephropathy [5]. In IDDM patients ESRD occurs in 25 to
35%, and the presence of microalbuminuria followed by a rise in
blood pressure suggests incipient diabetic nephropathy in these
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patients [7—10]. In contrast, several studies in white NIDDM
populations have shown that clinical proteinuria may be present in
23 to 30% of patients with nephropathy from non-diabetic causes
[11, 12].
We have initiated cross sectional and longitudinal studies of
renal function in black NIDDM subjects to determine the inter-
action of hypertension and diabetes and its relationship to albu-
minuria and renal disease. A preliminary report from our labora-
tory of data from 71 subjects showed that increasing duration of
diagnosed diabetes was associated with a decrease in renal
function as measured by glomerular filtration rate and renal
plasma blood flow [13, 14]. In subjects with new onset diabetes
hyperfiltration (defined as glomerular filtration rate greater than
140 ml/minhl.73 m2) was present in approximately 33%. This
paper expands on the previous report and presents the cross
sectional analysis of 194 black NIDDM subjects with and without
hypertension and a duration of NIDDM from 1 month to 36 years.
Methods
Study subjects
All patients who were referred to the Diabetes and Endocrine
clinics of SUNY-Health Science Center University Hospital and
the affiliated Kings County Hospital Center from 1986 to 1994
were asked to participate in the study. Subjects had NIDDM as
defined by the National Diabetes Data group [15]. The duration
of diagnosed NIDDM ranged from 1 month to 36 years. The study
protocol was approved by the Institutional Review Board at
SUNY-HSC Brooklyn. Subjects were enrolled after they signed an
informed consent. Subjects were studied after an overnight fast on
the Clinical Research Center. Medication for diabetes, if re-
quired, was not given during the morning of the study. Subjects
were considered to be hypertensive for the analyses if they had a
history of hypertension and were on medication or if their blood
pressures on several readings were 140 mm Hg systolic, 90 mm Hg
diastolic or higher, or the mean arterial pressure was greater than
or equal to 106. Eighty-four of the 99 hypertensive subjects were
on pharmacotherapy for their hypertension.
Methods
Glomerular filtration rate (GFR), the plasma volume filtered by
the kidney glomeruli per minute, and effective renal plasma flow
(RPF), the plasma volume perfusing the entire kidney per minute,
were measured in recumbent subjects by a constant infusion
technique with 125J iothalamate and 131j hippuran (Iso-Tex,
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Table 1. Characteristics of 117 black NIDDM subjects grouped
according to albumin excretion rates (AER)
> 300 mg/24 hr 30—300 mg124 hr 0—30 mg/24 hr
GFR
ml/min/1.73 m2 74.89 8.70 109.74 5.18k' 118.95 3.15a
RPF
mi/mm/i. 73 m2
Serum Cr mgldl
HbA1C ratio
Age years
Dur DM years
#HTN/total
aP < 0.0001, bP < 0.01, P < 0.05, compared to Group in column 1,
dp < 0.001, compared to Group in column 2
Friendswood, TX, USA) [16]. After the priming dose and a
60-minute equilibration period, urine samples were collected for
four 20 to 30 minute periods. Blood was drawn near the middle of
each period. Aliquots of plasma and urine were counted for 125!
and 131! in a dual channel gamma counter. GFR and RPF were
calculated from the standard clearance formulas. GFR and RPF
values were the mean of the values for the four periods and had
been corrected to 1.73 m2 body surface area. Ninety-one percent
of subjects had a coefficient of variance (CV) of less than 20%.
Nine percent of subjects had a CV of greater than 20%.
Glycohemoglobin was measured by either high-performance
liquid chromatography, column chromatography separation tech-
nique (Smith Kline, Los Angeles, CA, USA), or DCA 2000 (Miles
Diagnostics, Elkhard, IN, USA). Because of the different methods
used, all values were expressed as the percent of the upper limit of
the normal value for that method. Plasma glucose was measured
by glucose oxidase method with a Beckman glucose analyzer.
Urinary albumin measurements were assayed in 24-hour urine
collections using the Diagnostic Products Corporation Double
Antibody Albumin Kit.
Statistical analyses
Statistical analyses of the difference of the means were deter-
mined by the two-sample (2-tail) Student's t-test and by multiva-
nate analyses where indicated [17]. Data are presented as mean
SEM.
Renal function in non-diabetic reference subjects
GFR and RPF were determined in 10 age-matched non-
diabetic healthy subjects (4 men and 6 women) as previously
described [13]. None of the reference subjects had a history of
renal disease or hypertension. The mean SD age of the subjects
was 50 12 years. The mean SD of the GFR and RPF was 110
10 and 403 35 ml/min/1.73 m2, respectively.
Results
Subject characteristics presented according to urinary albumin
excretion rates
Table 1 shows the distribution of the 117 of the 194 subjects
who had urinary albumin excretion rates (AER) measured. A
mean decrease in GFR and RPF was not seen until clinical
proteinuria was present (AER > 300 mg/24 hr). This was coin-
cident with a mean rise in serum creatinine. The subjects with
AER > 300 mg/24 hr had a longer duration of diagnosed diabetes
314.54 35.24 397.21 21.64c 407.60 12.03"
1.69 0.05 1.07 0.05a 0.98 0.02
1.36 0.09 1.28 0.06 1.27 0.05
57.86 2.01 53.76 1.75 52.58 1.17
14.01 1.85 10.55 1.44 6.35 077c,d
14/14 20/25 42/78
AER mg/24 hr
< 30 30—300 > 300
Normotension
NIDDM < 1 Year 14 (100) 0 (0)
1—5 Years 6 (86) 1(14)
> 5—10 Years 10 (77) 3 (23)
> 10 Years 6 (86) 1(14)
Hypertension
NIDDM < 1 Year 5(71) 1(14) 1(14)
1—5 Years 12 (71) 4 (24) 1(6)
> 5—10 Years 18 (75) 4 (17) 2 (8)
> 10 Years 7 (25) 11(39) 10 (36)
as compared to subjects with AER <30 mg/24 hr. Moreover, all
subjects with AER > 300 mg/24 hr and 20 of 25 (80%) of subjects
with AER 30 to 300 mg/24 hr had hypertension as compared to
only 42 of 78 (54%) of subjects without significant albuminuria.
The presence of hypertension and the duration of diagnosed
diabetes correlated closely with increased urinary albumin excre-
tion (P < 0.0001 and P = 0.003, respectively). The data grouped
according to these parameters are shown in Table 2. No individual
without hypertension had an AER > 300 mg124 hr. Several
normotensive subjects with longer duration of diagnosed NIDDM
had microalbuminuria. In hypertensive NIDDM individuals mi-
croalbuminuria as well as clinical proteinuria were observed, and
an increase in its incidence correlated with longer duration of
diagnosed NIDDM. Eleven of 28 (39%) hypertensive subjects
with NIDDM> 10 years had microalbuminuria and an additional
10 (36%) had clinical proteinuria.
Since the presence of microalbuminuria and clinical proteinuria
correlated with the presence of hypertension and duration of
diagnosed NIDDM, renal function of 194 subjects is stratified
according to these parameters.
Subject characteristics presented according to presence of
hypertension and duration of diagnosed NIDDM
Table 3 lists the characteristics of the 194 black subjects with
NIDDM grouped according to duration of NIDDM: < 1 year,
1 to 5 years, > 5 to 10 years, and> 10 years; and the presence or
absence of hypertension. Normotensive subjects were slightly
younger than their hypertensive counterparts. Glycemic control as
measured by hemoglobin A1C (presented as a ratio of observed
value to upper limits of normal) and body mass index (BMI) were
similar for all groups compared. The duration of hypertension
varied from as little as 1 month to as long as 36 years. Fifty-one of
99 subjects with hypertension had the onset of their hypertension
prior to the diagnosis of NIDDM while 48 subjects had the onset
of hypertension after the diagnosis of NIDDM.
Glomerular filtration rate
Mean glomerular filtration rate (GFR) was similar for both
normotensive and hypertensive subjects with NIDDM < 1 year:
132.8 5.2 versus 123.8 7.8 ml/min/1.73 m2, respectively. In
those subjects without hypertension, increased duration of
NIDDM from ito 5 years, > 5 to 10 years, and> 10 years was not
associated with a decrease of mean GFR, 121.9 3.9, 129.1 5.1,
and 117.7 3.3 ml/min/1.73 m2, respectively (Fig. 1A). However,
Table 2. Urinary albumin excretion rates in 117 black NIDDM subjects
Data are number of subjects and in parentheses, percentage.
150 A Normotensive
0
- B Hypertensive
50
0
clYr 1—5Yr >5—lOYrs >lOYrs
Duration of NIDDM
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Table 3. Characteristics of the study subjects grouped according to duration of NIDDM and presence or absence of hypertension (absence of
hypertension represented by 0)
No. of subjects Gender M/F Ageyears
BMI
kg/rn2
HBA1C
(ratio)
DUR NIDDM DUR HTN
years
NIDDM < 1 year
27 15/12 46.2 2.0 29.18 0.92 1.28 0.08 0.33 0.04 0
15 8/7 50.1 2.5 30.63 1.30 1.10 0.03 0.45 0.08 4.05 1.50
NIDDM 1—5 years
38 23/15 44.5 1.6 28.60 0.84 1.24 0.09 2.66 0.22 0
19 9/10 52.2 2.6 28.74 0.83 1.27 0.08 2.59 0.27 9.63 2.39
NIDDM > 5—10 years
18 7/11 49.9 2.3 28.23 1.14 1.33 0.08 6.86 0.30 0
32 15/17 55.5 1.2 28.55 0.93 1.25 0.08 7.81 0.25 5.73 0.76
NIDDM > 10 years
12 2/10 55.0 2.4 28.41 1.08 1.37 0.08 19.17 2.16 0
33 11/22 58.4 1.1 30.02 0.81 1.34 0.06 16.94 0.82 10.85 1.46
the presence of hypertension with increasing duration of NIDDM,
1 to 5 years, > 5 to 10 years, and > 10 years, was associated with
a decrease in mean GFR for these groups as compared to
NIDDM matched normotensive subjects, 103.5 5.5 (P 0.008),
109.5 4.2 (P = 0.01), and 88.7 5.8 (P = 0.006) ml/min/1.73 m2,
respectively (Fig. 1B).
Renal plasma flow
Mean renal plasma flow (RPF) was decreased similarly only in
the hypertensive subjects with longer durations of NIDDM (Fig.
2B). In the hypertensive group, with duration of NIDDM > 5 to
10 years, RPF was decreased to 351.0 10.8 mi/min/m2, P =
0.00001, as compared to the normotensive group (RPF 474.5
26.6 ml/min/m2). In the hypertensive group with duration of
NIDDM > 10 years, RPF was also lower as compared to the
normotensive group (339.8 21.5 v. 434.8 28.1 ml/minhl.73 m2,
respectively, P = 0.02; Fig. 2).
Serum creatinine
An elevation in mean serum creatinine was seen in the hyper-
tensive groups with duration of NIDDM > 5 to 10 years and> 10
years (Fig. 3B). In the hypertensive group with duration of
NIDDM > 5 to 10 years, mean serum creatinine was 1.07 0.04
mg/dl, and in the normotensive group it was 0.92 0.04 mg/dl,
P = 0.014. With duration of NIDDM > 10 years, mean serum
creatinine was further increased in the hypertensive group to
1.37 0.11 mg/dl as compared to 0.91 0.04 mg/dl in the
normotensive group (P = 0.013; Fig. 3).
Impaired renal function
Clinical evidence of impaired renal function defined by a
GFR < 80 ml/min/1.73 m2 and or a serum creatinine> 1.4 mg/dl
was seen in only one of the subjects who was normotensive. In the
subjects with hypertension, a longer duration of NIDDM was
associated with increased prevalence of impaired renal function
(Table 4). With duration of NIDDM > 10 years, 12 of the 33
(36%) hypertensive subjects had either a GFR < 80 mi/min/1.73
2 and/or serum creatinine> 1.4 mg/dl.
Nine of the 14 (65%) subjects with AER > 300 mg/24 hr and
four of the 25 (16%) subjects with AER 30 to 300 mg/24 hour
(Table 2) had impaired renal function (GFR < 80 ml/min/1.73 m2
and/or a serum creatinine > 1.4 mg/dl). Five subjects with
impaired renal function had no microalbuminuria or proteinuria.
Fig. 1. Mean glornerular filtration rate as a function of duration of NIDDM
in norrnotensive (A) and hypertensive (B) subjects. The mean GFR in the
normotensive subjects with duration of NIDDM < 1 year was 132.8 5.2,
1—5 years was 121.9 3.9, > 5—10 years was 129.1 5.1, and > 10 years
was 117.7 3.3 ml/min/1.73 m2. In comparison, the hypertensive subjects
with duration of NIDDM < 1 year, the mean GFR was 123.8 7.8
ml/min/1.73 m2 (P = NS), 1—5 years was 103.5 5.5 (P = 0.008), > 5—10
years was 109.5 4.2 (P = 0.01), and > 10 years was 88.7 5.8
ml/min/1.73 m2 (P = 0.006).
Urine samples were not available in four other subjects with
impaired renal function.
Blood pressure
The mean systolic and diastolic blood pressure at the time of
the isotopic GFR and RPF for each group of subjects is shown in
500
A Normotenslve 1.50 - A Normotensive
I
1.00
C
C
0.50
0.00
0
500 B Hypertensive
1.50 . B Hypertensive
200
0
I
ID 1.00C
C
clYr 1—5Yrs >5—lOYrs >lOYrs
ura1ion gf NIQM
<lYr 1—5Yrs >5—lOYrs >lOYrs
Duration of NIDDM
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Fig. 2. Mean renal plasma flow as a function of duration of NIDDM in
normotensive (A) and hypertensive (B) subjects. The mean RPF in the
normotensive subjects with duration of NIDDM < 1 year was 472.5
24.3, 1—5 years was 415.8 21.3, > 5—10 years was 474.5 26.6, and> 10
years was 434.8 28.1 ml!min!l.73 m2. In comparison, for the hyperten-
sive subjects with duration of NIDDM < 1 year, the mean RPF was 417.4
36.5 ml/min/l.73 m2 (P = NS), 1—5 years was 375.7 19.8 (P = NS),>
5-10 years was 351.0 10.8 (P = 0.00001), and > 10 years was 339.8
21.5 ml/min/1.73 m2 (P = 0.02).
Table 5. The normotensive subjects had similar mean blood
pressure independent of duration of NIDDM. In the hypertensive
subjects the mean diastolic blood pressure was also similar. The
mean systolic blood pressure was highest in the hypertensive
group with the longest duration of NIDDM as compared to the
other hypertensive groups.
Effect of duration of NIDDM and blood pressure on GFR
Multiple linear regression analysis was performed on the hy-
pertensive group to determine the independent effects of duration
of NIDDM and hypertension on GFR. The correlation coefficient
for duration of NIDDM was —0.3632 (P 0.0002) and for
duration of hypertension was —0.1478 (P 0.122). Thus the
duration of NIDDM and the existence of hypertension, but not its
duration, have a detrimental effect on GFR in this cross sectional
analysis.
Table 6 shows the relationship between hypertension existing
prior to the diagnosis of NIDDM versus that developing during
the course of NIDDM on the subsequent loss of renal function.
Approximately 50% of individuals who had hypertension diag-
nosed preceding or simultaneously with the diagnosis of NIDDM
had decreased renal function after five years of diabetes.
Fig. 3. Mean semm creatinine as a function of duration of NIDDM in
normotensive (A) and hypertensive (B) subjects. The mean serum creatinine
in the normotensive subjects with duration of NIDDM < 1 year was
1.00 0.05, 1—5 years was 1.07 0.03, > 5—10 years was 0.92 0.04, and
> 10 years was 0.91 0.04 ml!min!1.73 m2. In comparison, the hyperten-
sive subjects with duration of NIDDM < 1 year, the mean serum
creatinine was 1.05 0.62 mllmin/1.73 m2 (P = NS), 1—S years was 1.09
0.08 (P = NS), > 5-10 years was 1.07 0.04 (P = 0.014), and> 10 years
was 1.37 0.11 ml/min/1.73 m2 (P = 0.013).
Table 4. Impaired renal function in black NIDDM subjects
GFR <80 ml!
min!1.73 m2 &/or
Serum Cr> 1.4
Total mg/dl
number No. %
Normotension
NIDDM < 1 year 27 0
1—5 years 38 1 3
> 5—10 years 18 0
> 10 years 12 0
Hypertension
NIDDM < 1 year 15 2 13
1—5 years 19 4 21
> 5—10 years 32 4 13
> 10 years 33 12 36
Total number is the number of subjects for each subset. Data
number of subjects and percentage with impaired renal function.
are
In contrast, of those individuals who developed hypertension
during the course of their NIDDM, 12% (2 of 17 subjects) with
NIDDM > 5 to 10 years and 85% (17 of 20 subjects) with
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Table 5. Blood pressure in the 194 black NIDDM subjects
Normotensive Hypertensive
NIDDM < 1 year
BP SYSTOLIC 117 2 141 3
BP DIASTOLIC 80± 2 94 2
1—5 years
BP SYSTOLIC 120 2 142 4
BP DIASTOLIC 79 2 93 2
> 5—10 years
BP SYSTOLIC 116 3 144 3
BP DIASTOLIC 78 2 94 2
> 10 years
BP SYSTOLIC 118 3 153 3
BP DIASTOLIC 80 2 91 2
NIDDM > 10 years demonstrated at least one of the following:
GFR < 80 ml/min/1.73 m2, serum creatinine> 1.4 mg/dl, and/or
microalbuminuria or clinical proteinuria. Thus, clinical signs of
nephropathy were present in a significantly higher percentage of
subjects with NIDDM > 10 years who had developed hyperten-
sion during their course of NIDDM (mean duration of hyperten-
sion 5.75 1.05 years) as compared to the other hypertensive
subjects with a mean duration of hypertension of 18.69 1.79
years (17 of 20 vs. 7 of 13; P < 0.05).
Discussion
NIDDM patients develop diabetic nephropathy at variable
rates [1, 2]. The incidence of end-stage renal disease in NIDDM
is higher in blacks than in whites when adjustments are made for
the differences in prevalence rates of NIDDM between the races
[3]. Blacks also have a higher prevalence rate of hypertension than
whites, and consequently have a greater rate of ESRD secondary
to hypertension [2, 6]. The respective influence of these comorbid
conditions, diabetes and hypertension, in the acceleration of the
development of renal impairment in black subjects is unclear.
This study presents the cross sectional data of renal function in
black subjects with NIDDM. When 117 subjects are grouped
according to urinary albumin excretion rates, clinical proteinuria
and hypertension are associated with a decrease in GFR and RPF
and a rise in serum creatinine. The presence of albuminuria is
associated with longer durations of diagnosed diabetes. Further
analysis of data from 194 subjects grouped according to duration
of diagnosed diabetes and the absence or presence of hyperten-
sion data show that (1) black subjects with varying durations of
diagnosed NIDDM who maintain normotension have normal
renal function as assessed by GFR, RPF and serum creatinine. No
NIDDM individual remaining normotensive had clinical protein-
uria, though several had microalbuminuria; (2) hypertensive black
subjects with a duration of diagnosed NIDDM of ito 5 years have
decreased GFR as compared to normotensive black subjects with
the same duration of diagnosed NIDDM; (3) hypertension in
black subjects with longer durations of diagnosed NIDDM is
associated with a further decrease in GFR, a decrease in RPF, a
rise in serum creatinine, and an increase in microalbuminuria and
clinical proteinuria; and (4) with diagnosed NIDDM > 10 years
duration, 36% of hypertensive subjects have impaired renal
function as measured by GFR < 80 ml/min/1.73 m2 and/or serum
creatinine> 1.4 mg/dl, and 75% of the hypertensive subjects who
had urinary albumin excretion rates measured have microalbu-
minuria or significant proteinuria.
Table 6. Relationship of the onset of hypertension prior to or after the
diagnosis of NIDDM to the subsequent development of abnormal
renal function
Hypertension Hypertension
preceding following
Duration of NIDDM NIDDM NIDDM
NIDDM > 5—10 years 6/15 (40) 2/17 (12)
NIDDM > 10 years 7/13 (54) 17/20 (85)
Abnormal renal function is defined as one or more of the following:
GFR < 80 ml/min/1.73 rn2, serum creatinine> 1.4 mg/dl, urinaly albumin
excretion rate 30 to 300 or > 300 mg/24 hr. Data are the number of
subjects with abnormal renal function versus the total number of subjects
in the subset (percentage).
a P < 0.05
Renal impairment can be due to either diabetes, hypertension,
or a combination of both, and it affects populations differently. In
white NIDDM populations, hypertension which often precedes or
develops simultaneously with NIDDM does not uniformly herald
a subsequent decline in renal function, as evidenced by the low
rate of ESRD reported in that population [18—20]. Yet, Ravid et
al [20], in a 14 year follow-up report on 195 NIDDM patients,
have shown a significant association between recent elevations of
blood pressure including within the normal range and impaired
renal function. Furthermore, the presence of microalbuminuria, a
strong predictor of nephropathy in IDDM patients, correlates
with the presence of macrovasular disease and its associated
mortality, and may not predict diabetic nephropathy in white
NIDDM individuals [21—25]. Other studies have shown that
clinical proteinuria in white NIDDM subjects can be the result of
non-diabetic nephropathy in as many as 23 to 30% of subjects [11,
12].
In non-white NIDDM populations such as Mexican Americans
and Pima Indians the prevalence of diabetic nephropathy is high.
This is in spite of the relatively low prevalence rate of hyperten-
sion in these populations as compared to non-Hispanic whites [1,
2, 4, 5]. In both these non-white NIDDM populations, microalbu-
minuria and the subsequent development of hypertension strongly
correlate with incipient nephropathy and, if untreated result in an
accelerated course to renal failure. This is similar to the course of
progression of diabetic nephropathy seen in IDDM in which the
presence of microalbuminuria and the development of hyperten-
sion predict the development of clinical nephropathy [7—9]. Par-
ving et al reported cross sectional data from 957 IDDM patients
showing that the degree of albuminuria correlated with the
increased prevalence of hypertension, proliferative retinopathy,
and peripheral neuropathy [8]. Berglund et al demonstrated that
normotensive IDDM patients with microalbuminuria had higher
blood pressure as compared to those without microalbuminuria
[9]. Though most studies suggest that microalbuminuria develops
prior to the development of hypertension and renal impairment,
recent reports have shown that in a subset of IDDM patients
diabetic nephropathy can occur without proteinuria [26, 27].
Data from 116 black NIDDM subjects, reported by Dasmaha-
patra et al showed that increases in blood pressure were seen in
the groups with micro- and macroalbuminuria as compared to the
group without albuminuria [28]. Previously we reported data from
71 black NIDDM subjects and showed that duration of diagnosed
NIDDM correlated with decrease in GFR. However, almost all of
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the subjects with NIDDM of long duration also had hypertension
[13].
Thus renal impairment is predictably accompanied by eleva-
tions in blood pressure. Our normotensive diabetic subjects do not
exhibit early clinical changes in renal function regardless of
duration of diabetes. Interestingly, mean systolic and diastolic
blood pressures are no different in the older subjects with longer
durations of diabetes as compared to the younger subjects with
shorter durations of diabetes.
The impact of hypertension on the development of renal
disease in NIDDM subjects is complex. Hypertension which
precedes or is diagnosed concurrently with diabetes is caused by
metabolic abnormalities other than hyperglycemia, and can over
the course of years decrease renal function through its vascular
effects. Hypertension which occurs during the course of diabetes is
likely to be due to the renal consequences of hyperglycemia.
Our data suggest that the coexistence of hypertension and
NIDDM affects renal function as early as one to five years after
the diagnosis of diabetes. However, it is in those subjects with
NIDDM for greater than 10 years and hypertension who are most
likely to develop nephropathy. Hypertension subsequent to the
onset of NIDDM confers the greatest risk. It is possible that the
subjects with long duration of diagnosed NIDDM, who recently
develop hypertension, will follow a course similar to that reported
in IDDM patients. Our longitudinal studies of renal function in
our cohort will determine the time course in the development of
albuminuria and rise in blood pressure, and clarify the temporal
relationship between diabetes and hypertension in the develop-
ment of renal disease in black NIDDM patients.
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